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IN THE ENVIRONMENT ‒ NEW METHODS OF REMOVAL
LEKI BETA-ADRENOLITYCZNE (β-BLOKERY) 
W ŚRODOWISKU ‒ NOWE METODY ELIMINACJI
A b s t r a c t
This paper is part of a series of publications discussing the prevalence of pharmaceuticals in the 
aquatic environment and the effectiveness of their removal and degradation during wastewater 
and water treatment processes. It presents the most commonly used b-blockers and their 
parameters related to their metabolism and excretion from a body. In the paper, the authors 
review the literature data on the presence of b-blockers in wastewater and surface waters 
and present new solutions which have been developed  to  increase  the efficiency of  removal 
of these compounds from wastewater and potable water.
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Economic factors effectively limit the range of solutions that would ultimately 
prevent a discharge of drugs and other organic substances into rivers. The application 
of some methods used in water treatment could enhance the degradation of pharmaceuticals 
during  wastewater  treatment,  but  at  the  same  time,  it  would  significantly  increase 
the treatment costs of municipal wastewater. Therefore, articles reporting the presence 
of specific pharmaceuticals in aqueous environments are regularly published. They not only 
address the issue of popular and over-the-counter pharmaceuticals such as non-steroidal 
anti-inflammatory  drugs  [17],  but  also  cytostatic  drugs  used  in  chemotherapy  and  the 
treatment of autoimmune diseases [2]. According to Wegrzyn et. al. [22] b-blocker drugs 
are ranked third among pharmaceuticals most commonly present in the aquatic environment. 
Due to the nature of b-blockers, they should not be present in water intended for human 
consumption.
2. Characteristic of β-blockers
b-adrenergic receptor blockers are pharmaceuticals that block b-1 and b-2 adrenergic 
receptors to reduce the effects caused by adrenaline and noradrenaline i.e. they act upon the 
sympathetic nervous system. Their action results in a slower heartrate, lower blood pressure 
and smooth muscle contraction. They are divided into two groups: non-selective (generally 
affecting adrenergic receptors) and selective, mainly blocking b-1  receptors  (described as 
cardio selective). b-blockers are used not only in the treatment of diseases such as coronary 
heart disease, hypertension, heart rhythm disorders and glaucoma, but also in anxiety 
disorders and neuroses. Table 1 shows the most common b-blockers.
T a b l e  1
Characteristics of β-blockers [25‒33]






























































3. β-blockers in the environment
Both common and uncommon sources of pharmaceuticals in the aquatic environment 
and  soil  are  shown  in  Figure  1  [10].  b-blockers, as drugs used primarily in treatments 
of a cardiac nature, should be expected primarily in wastewater from households and hospitals. 
Fig. 1. Pharmaceuticals in water and soil
99
The concentration of  the drugs may vary significantly, due  to  its prevalence, dose and  its 
metabolic pathway in the body (some of them, such as nadolol or sotalol, are not metabolised). 
Therefore, there may not be an actual relationship between the occurrence of a particular 




was the b-blocker the most widely used by the inhabitants of Bitz. However, when considering 
the excretion of the unchanged drug (MET 5%, SOT 100%), metoprolol was found to be the 





researchers  attributed  their  presence  to  insufficient  removal  of  these  compounds  during 
the  wastewater  treatment  process  [18].  The  concentrations  of  b-blocker pharmaceuticals 
in wastewater and surface water reported in the literature are presented in Tab. 2.
T a b l e  2
Concentrations in ng/l (min-max or mean ± σ) of detected β-blockers in WWTP influent, 
WWTP effluent and surface water
















































Timolol 10‒16[20] 1‒13[20] ‒
Recent studies have shown that b-blockers are poorly adsorbable by soil structure and 
show good water solubility [14]; therefore, there is a risk of their penetration to groundwater. 
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This  view  is  supported  by  the  literature,  since  the  metabolites  of  atenolol  (6.4  ng/l)  [8] 
and  propranolol  (5‒21.4 ng/l) [11] have been detected in groundwater. The presence 
of b-blockers in the water coming to water treatment plants could threaten to reach the 
consumers of drinking water ‒ such cases were confirmed by studies showing the presence 
of atenolol, among other pharmaceuticals, in water for human consumption (0.82‒23 ng/l) [3].
4. New methods of β-blocker removal
One of the newest methods of b-blockers degradation is the application of K2Fe
VIO4 
used in the advanced oxidation of actual hospital wastewater [23]. Studies have shown 
a more than 90% degradation of ATE, MET and PRO. However, during the process, many 
pharmaceutical oxidation by-products were formed, while the biodegradability of the 
system was only slightly increased. According to the authors [23], the proposed method 
can be implemented in water or wastewater treatment only after thorough research on 
process mechanisms and advanced oxidation by-products formed during the process.
Photocatalysis also appears to be an effective tool in the degradation of pharmaceuticals. 
100% elimination of MET after 2 h of irradiation was achieved using a new nanocomposite 
consisting of Ag‒Bi2‒WO6 and graphene [24], which the authors define as a motivating factor 
for the development of new photocatalysts and their use in wastewater treatment.
In  [21],  the  authors  compared  the  efficiency  of  advanced  oxidation  in  removing 
pharmaceuticals from hospital wastewater. In the case of atenolol, bisoprolol, metoprolol, 
propranolol and sotalol, the most effective method of removal was H2O2-assisted ozonation. 




– Pharmaceuticals are commonly found in wastewater and surface waters.
– The  efficiency  of  b-blocker  degradation  is  related  to  the  efficiency  of  wastewater 
treatment processes which reduce the pollution of the aquatic environment.
– β-blockers, as drugs that are water soluble and poorly adsorbable on soil, can penetrate 
into groundwater and accumulate in plants.
– Since there is no research data on the long-term impact of b-blockers on the human 
body, attempts should be made to fully eliminate these substances during water treatment 
processes.
– Newly developed technological solutions for b-blocker degradation are a good prognostic 
for the safety of drinking water in the future.
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